Clinical Trials List
Protocol NumberPolaris 2016-001
NCT Number(ClinicalTrials.gov Identfier)NCT02875093
Completed
2017-05-16 - 2019-09-30
Phase I
Terminated3
ICD-10C92
Myeloid leukemia
Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia
-
Trial Applicant
-
Sponsor
Polaris Group
-
Trial scale
Taiwan Multiple Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 洪玉馨 Division of Hematology & Oncology
- Tung-Liang Lin Division of Hematology & Oncology
- 湯崇志 Division of Hematology & Oncology
- Ming-Chung Kao Division of Hematology & Oncology
- Po-Nan Wang Division of Hematology & Oncology
- 高小雯 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Principal Investigator
Co-Principal Investigator
- Hui-Hua Hsiao Division of Hematology & Oncology
- 卓士 醫師 Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
- Shih-Feng Cho Division of Hematology & Oncology
- Ta-Chih Liu Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- 蔡郁棻 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Ya-Ting Hsu Division of General Internal Medicine
- Sin-Syue Li Division of General Internal Medicine
- Yu-Min Yeh Division of General Internal Medicine
- Hui-Jen Tsai Division of General Internal Medicine
- Shang-Yin Wu Division of General Internal Medicine
- Wei-Pang Chung Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
6 Stop recruiting
Audit
None
Condition/Disease
Acute Myeloid Leukemia
Objectives
Primary Outcome Measures :
Incidence of Treatment-Emergent Adverse Events .
Test Drug
ADI-PEG 20
Active Ingredient
Arginine degrading enzyme, ADI, coupled to PEG.
Dosage Form
Injection
Dosage
11.0 ±1.0 mg/ml
Endpoints
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease
Inclution Criteria
Inclusion Criteria:
AML diagnosed by morphologic (with >20% blasts in blood or bone marrow) and histochemical and/or cell surface marker criteria.
Patients with AML must fall into one of the following:
Patients with AML (i.e., > 20% bone marrow blasts) who are deemed unfit* for intensive chemotherapy with refractory or relapsed disease. The patients must have been refractory to at least one cycle of cytarabine containing regimens or at least two cycles of azacitidine or similar hypomethylating agents.
Patients with untreated AML (i.e., > 20% bone marrow blasts) with intermediate risk karyotype (MRC risk group) who are deemed unfit for intensive chemotherapy.
Patients with untreated AML with adverse risk karyotype (MRC risk group) who are deemed unfit for intensive chemotherapy and who are intolerant of azacitidine (or other hypomethylating agents) or who are unable to access azacitidine or other hypomethylating agents.
Patients unfit for conventional intensive chemotherapy are defined as having at least one of the following based on the conceptual criteria of Ferrara (2013):
Advanced age (over 75 years).
Cardiac impairment with ejection fraction ≤ 50% or heart failure (NYHA class 2) or ischemic heart disease with stable angina.
Pulmonary impairment: chronic obstructive pulmonary disease (COPD) stage 1-2 (forced expiratory volume in one second [FEV1] > 49%) or other comparable respiratory disease with forced vital capacity (FVC) > 50%.
Hepatic comorbidity with Child-Pugh grade A cirrhosis
Chronic kidney disease stage 3 but with creatinine clearance > 30 mls/min
Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy.
Age > 17 years.
ECOG performance status of 0-2.
Bone marrow aspirate and/or biopsy for testing for ASS1-deficiency. This must be a fresh sample obtained after any prior chemotherapy and before enrollment in this study. ASS1-deficiency is not required for study entry, but the fresh bone marrow sample must be processed either before or within 1 week of first study dose (see Section 10 for more details).
AML diagnosed by morphologic (with >20% blasts in blood or bone marrow) and histochemical and/or cell surface marker criteria.
Patients with AML must fall into one of the following:
Patients with AML (i.e., > 20% bone marrow blasts) who are deemed unfit* for intensive chemotherapy with refractory or relapsed disease. The patients must have been refractory to at least one cycle of cytarabine containing regimens or at least two cycles of azacitidine or similar hypomethylating agents.
Patients with untreated AML (i.e., > 20% bone marrow blasts) with intermediate risk karyotype (MRC risk group) who are deemed unfit for intensive chemotherapy.
Patients with untreated AML with adverse risk karyotype (MRC risk group) who are deemed unfit for intensive chemotherapy and who are intolerant of azacitidine (or other hypomethylating agents) or who are unable to access azacitidine or other hypomethylating agents.
Patients unfit for conventional intensive chemotherapy are defined as having at least one of the following based on the conceptual criteria of Ferrara (2013):
Advanced age (over 75 years).
Cardiac impairment with ejection fraction ≤ 50% or heart failure (NYHA class 2) or ischemic heart disease with stable angina.
Pulmonary impairment: chronic obstructive pulmonary disease (COPD) stage 1-2 (forced expiratory volume in one second [FEV1] > 49%) or other comparable respiratory disease with forced vital capacity (FVC) > 50%.
Hepatic comorbidity with Child-Pugh grade A cirrhosis
Chronic kidney disease stage 3 but with creatinine clearance > 30 mls/min
Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy.
Age > 17 years.
ECOG performance status of 0-2.
Bone marrow aspirate and/or biopsy for testing for ASS1-deficiency. This must be a fresh sample obtained after any prior chemotherapy and before enrollment in this study. ASS1-deficiency is not required for study entry, but the fresh bone marrow sample must be processed either before or within 1 week of first study dose (see Section 10 for more details).
Exclusion Criteria
Exclusion Criteria:
A subject will not be eligible for study participation if he/she meets any of the exclusion criteria:
Patients with uncontrolled infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study; patients on prophylactic antibiotics or antivirals are acceptable.
Pregnancy or lactation.
Expected non-compliance.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), unstable angina, ventricular cardiac arrhythmia (other than ventricular ectopy), severe pulmonary comorbidity: COPD grade 3-4 (FEV1 <50%) or other comparable documented pulmonary disease with FVC <50%, or dyspnea at rest or requiring oxygen at home, cognitive impairment: current mental illness requiring psychiatric hospitalization, institutionalization or intensive outpatient management, or uncontrolled current cognitive status (as confirmed by the specialist; dependence on a caregiver is permitted as long as this is well controlled), severe hepatic comorbidity: liver Child-Pugh grade B-C cirrhosis or acute viral hepatitis, social situations that would limit compliance with study requirements or DIC causing coagulopathy not correctable with factor replacement.
Subjects who have had any anti-leukemia treatment prior to entering the study and have not recovered to baseline (except alopecia) or≤ Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and Investigator may be allowed upon agreement with both.
A subject will not be eligible for study participation if he/she meets any of the exclusion criteria:
Patients with uncontrolled infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study; patients on prophylactic antibiotics or antivirals are acceptable.
Pregnancy or lactation.
Expected non-compliance.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), unstable angina, ventricular cardiac arrhythmia (other than ventricular ectopy), severe pulmonary comorbidity: COPD grade 3-4 (FEV1 <50%) or other comparable documented pulmonary disease with FVC <50%, or dyspnea at rest or requiring oxygen at home, cognitive impairment: current mental illness requiring psychiatric hospitalization, institutionalization or intensive outpatient management, or uncontrolled current cognitive status (as confirmed by the specialist; dependence on a caregiver is permitted as long as this is well controlled), severe hepatic comorbidity: liver Child-Pugh grade B-C cirrhosis or acute viral hepatitis, social situations that would limit compliance with study requirements or DIC causing coagulopathy not correctable with factor replacement.
Subjects who have had any anti-leukemia treatment prior to entering the study and have not recovered to baseline (except alopecia) or≤ Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and Investigator may be allowed upon agreement with both.
The Estimated Number of Participants
-
Taiwan
22 participants
-
Global
22 participants
